Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, specialty drug maker Hi-Tech Pharmacal (NASDAQ: HITK) has earned a respected four-star ranking.
With that in mind, let's take a closer look at Hi-Tech and see what CAPS investors are saying about the stock right now.
Hi-Tech facts
|
Headquarters (founded) |
Amityville, N.Y. (1982) |
|
Market Cap |
$435.2 million |
|
Industry |
Pharmaceuticals |
|
Trailing-12-Month Revenue |
$225.8 million |
|
Management |
Chairman/CEO David Seltzer (since 1998) |
|
Return on Equity (average, past 3 years) |
24.5% |
|
Cash/Debt |
$92.3 million/$1.5 million |
|
Competitors |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 92% of the 222 members who have rated Hi-Tech believe the stock will outperform the S&P 500 going forward.
Just last week, one of those Fools, arrowboy, tapped Hi-Tech as a particularly attractive growth opportunity:
Using Peter Lynch motivated stock screen found this gem. Good growth in revenue and EPS. P/E less than half the [three-year EPS growth rate]. Still small enough to grow substantially at <$500M mkt cap. The single negative is the high institutional ownership (>60%) which brings the analysts following as well.
If you want market-beating returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its strong four-star rating, Hi-Tech may not be your top choice.
We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
